EP3382002B1 - Composition for contact lens - Google Patents
Composition for contact lens Download PDFInfo
- Publication number
- EP3382002B1 EP3382002B1 EP17190771.0A EP17190771A EP3382002B1 EP 3382002 B1 EP3382002 B1 EP 3382002B1 EP 17190771 A EP17190771 A EP 17190771A EP 3382002 B1 EP3382002 B1 EP 3382002B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- contact lens
- algefacient
- surfactant
- lens according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 28
- 239000004094 surface-active agent Substances 0.000 claims description 15
- 229920003169 water-soluble polymer Polymers 0.000 claims description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 8
- NTYZDAJPNNBYED-UHFFFAOYSA-M sodium;2-(2-dodecanoyloxypropanoyloxy)propanoate Chemical group [Na+].CCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O NTYZDAJPNNBYED-UHFFFAOYSA-M 0.000 claims description 6
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 5
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 5
- 229940041616 menthol Drugs 0.000 claims description 5
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 4
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 4
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 4
- JDRMYOQETPMYQX-UHFFFAOYSA-M 4-methoxy-4-oxobutanoate Chemical compound COC(=O)CCC([O-])=O JDRMYOQETPMYQX-UHFFFAOYSA-M 0.000 claims description 4
- 241000723346 Cinnamomum camphora Species 0.000 claims description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 4
- UJNOLBSYLSYIBM-WISYIIOYSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2r)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O UJNOLBSYLSYIBM-WISYIIOYSA-N 0.000 claims description 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 4
- 239000004327 boric acid Substances 0.000 claims description 4
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 4
- 229940116229 borneol Drugs 0.000 claims description 4
- JDRMYOQETPMYQX-UHFFFAOYSA-N butanedioic acid monomethyl ester Natural products COC(=O)CCC(O)=O JDRMYOQETPMYQX-UHFFFAOYSA-N 0.000 claims description 4
- 229930008380 camphor Natural products 0.000 claims description 4
- 229960000846 camphor Drugs 0.000 claims description 4
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 4
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 claims description 3
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 claims description 3
- 229910021538 borax Inorganic materials 0.000 claims description 3
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 claims description 3
- 229930007503 menthone Natural products 0.000 claims description 3
- LMXFTMYMHGYJEI-UHFFFAOYSA-N p-menthane-3,8-diol Chemical compound CC1CCC(C(C)(C)O)C(O)C1 LMXFTMYMHGYJEI-UHFFFAOYSA-N 0.000 claims description 3
- 229930006948 p-menthane-3,8-diol Natural products 0.000 claims description 3
- 239000004328 sodium tetraborate Substances 0.000 claims description 3
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 3
- OXJGJKIURHREKH-UHFFFAOYSA-O CC(=C)C(=O)OCCP(=O)=C(O)C[N+](C)(C)C Chemical compound CC(=C)C(=O)OCCP(=O)=C(O)C[N+](C)(C)C OXJGJKIURHREKH-UHFFFAOYSA-O 0.000 claims 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims 1
- 230000035807 sensation Effects 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000001491 myopia Diseases 0.000 description 4
- 230000004379 myopia Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000003761 preservation solution Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- -1 sodium tetraborate) Chemical compound 0.000 description 2
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 206010052140 Eye pruritus Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001616 Polymacon Polymers 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/0005—Other compounding ingredients characterised by their effect
- C11D3/0078—Compositions for cleaning contact lenses, spectacles or lenses
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
- C11D1/02—Anionic compounds
- C11D1/04—Carboxylic acids or salts thereof
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
- C11D1/02—Anionic compounds
- C11D1/12—Sulfonic acids or sulfuric acid esters; Salts thereof
- C11D1/14—Sulfonic acids or sulfuric acid esters; Salts thereof derived from aliphatic hydrocarbons or mono-alcohols
- C11D1/146—Sulfuric acid esters
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
- C11D1/02—Anionic compounds
- C11D1/12—Sulfonic acids or sulfuric acid esters; Salts thereof
- C11D1/29—Sulfates of polyoxyalkylene ethers
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
- C11D1/02—Anionic compounds
- C11D1/34—Derivatives of acids of phosphorus
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
- C11D1/66—Non-ionic compounds
- C11D1/667—Neutral esters, e.g. sorbitan esters
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
- C11D1/66—Non-ionic compounds
- C11D1/72—Ethers of polyoxyalkylene glycols
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/18—Hydrocarbons
- C11D3/188—Terpenes
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/20—Organic compounds containing oxygen
- C11D3/2003—Alcohols; Phenols
- C11D3/2006—Monohydric alcohols
- C11D3/2024—Monohydric alcohols cyclic; polycyclic
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/20—Organic compounds containing oxygen
- C11D3/2003—Alcohols; Phenols
- C11D3/2006—Monohydric alcohols
- C11D3/2037—Terpenes
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/20—Organic compounds containing oxygen
- C11D3/2003—Alcohols; Phenols
- C11D3/2041—Dihydric alcohols
- C11D3/2062—Terpene
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/20—Organic compounds containing oxygen
- C11D3/2093—Esters; Carbonates
Definitions
- the instant disclosure relates to a composition for contact lenses; in particular, to a composition for contact lenses which can serve as a contact lens preservation solution.
- Smartphones and computers are used frequently in today's information society, resulting in an increase in the population with myopia and a decrease in the age group of myopia.
- it is generally a good choice for people with myopia to wear contact lenses.
- most people with myopia need to wear contact lenses for extended periods of time.
- the material of the conventional contact lenses have been constantly improved to meet various requirements such as high water content and high oxygen permeability, the wearers thereof would still suffer from eye dryness due to decreased water content and experience eye discomfort due to dirt or secretion. Therefore, there is an urgent need for a maintenance solution that can be used to clean, rehydrate and preserve contact lenses.
- US2017056335 A1 discloses an ophthalmic composition comprising polysorbate 80 and a refreshing agent.
- WO9603158 A1 and US 6 228 323 B1 disclose compositions for contact lenses which include sodium lauroyl lactylate.
- One aspect of the instant disclosure relates to a composition for contact lens which allows a contact lens wearer's eyes to feel comfortable during the period of initial wear and extended periods of continuous wear.
- the composition for contact lenses includes an algefacient and a surfactant, and a water soluble polymer, wherein the surfactant is sodium lauroyl lactylate, wherein the algefacient includes one or a combination of menthol, camphor, borneol, menthyl lactate, menthone glycerol ketal, monomethyl succinate, and p-menthane-3,8-diol; and wherein the water soluble polymer includes PEG 400 and MPC in a molar ratio of 1:20.
- the surfactant is sodium lauroyl lactylate
- the algefacient includes one or a combination of menthol, camphor, borneol, menthyl lactate, menthone glycerol ketal, monomethyl succinate, and p-menthane-3,8-diol
- the water soluble polymer includes PEG 400 and MPC in a molar ratio of 1:20.
- the algefacient and the surfactant wherein the surfactant is sodium lauroyl lactylate and the expression of the algefacient in the composition of a contact lens can be performed effectively. Therefore, the discomfort and foreign matter sensation in the eyes of contact lens wearers can be reduced or relieved, providing long-lasting cool and moist sensations to the eyes.
- Fig. 1 is a perspective view showing a contact lens and a composition for contact lenses according to the instant disclosure in a container.
- the instant disclosure provides a composition for contact lenses which can serve as a preservation solution and be hermetically sealed with the contact lenses in a container.
- the contact lenses are immersed in direct contact with the composition.
- the user takes the contact lens out of the composition and put the contact lenses on his/her eyes. More specifically, the ingredients of the composition absorb onto the surface of the contact lenses and then transfer into the user's eyes.
- the composition according to the instant embodiment is intended for use in connection with soft and rigid contact lenses.
- soft contact lens can refer to a hydrous soft contact lens made from hydrogels (i.e., hydrogel contact lenses) and a non-hydrous soft contact lens made from copolymers of butyl acrylate and butyl methacrylate.
- the composition according to the instant embodiment is applicable to the soft contact lenses in U.S. FDA category Group I-IV.
- Group I-IV lenses often contain materials identified in the market as: alphafilcon, asmofilcon, balafilcon, ethafilcon, hefilcon, hilafilcon, lidofilcon, lotrafilcon, methafilcon, nelfilcon, ocufilcon, omafilcon, phemfilcon, polymacon, tefilcon, tetrafilcon, vasurfilcon, vifilcon, senofilcon, galyfilcon, enfilcon, comfilcon, narafilcon, delefilcon, efrofilcon, and filicon II 3.
- the composition according to the instant embodiment mainly includes a base solution, an algefacient, a surfactant, and a water soluble polymer.
- the algefacient, the surfactant, and the water soluble polymer are uniformly dispersed in the base solution.
- the base solution is a physiological saline solution with a buffer containing boric acid or phosphorous acid.
- the buffer has a pH buffering capacity and is configured to adjust the pH of the composition to a pH between 6.8 and 7.6.
- the base solution can include an appropriate amount of sodium chloride or potassium chloride to maintain the osmolality of the composition at a value between 250 Osmol/Kg and 350 Osmol/Kg.
- the buffer can be selected from boric acid, borate (e.g., sodium tetraborate), phosphorous acid, or phosphate (e.g., sodium hydrogen phosphate and sodium dihydrogen phosphate). It should be noted that a buffer may be used alone or two or more different buffers may be used in combination in the base solution. In addition, the concentration of the buffer may be appropriately adjusted depending on its kind or the kind of the other ingredients.
- the algefacient is added to reduce or relieve the discomfort and foreign matter sensation in the eyes and give the eyes a cool, fresh sensation.
- the algefacient includes one or a combination of menthol, camphor, borneol, menthyl lactate, menthone glycerol ketal, monomethyl succinate, and p-menthane-3,8-diol.
- the content of the algefacient is in the range between 0.001% (w/v) and 0.5 % (w/v), preferably between 0.001% (w/v) and 0.25 % (w/v), to avoid irritating the eye.
- the surfactant is added to clean and moisturize a contact lens, in which protein and lipid deposits on the surfaces of the contact lens can be removed.
- the surfactant is sodium lauroyl lactylate.
- the content of the surfactant is in the range between 0.001% (w/v) and 2% (w/v), and preferably between 0.001% (w/v) and 0.5 % (w/v).
- the expression of the algefacient in the composition for contact lenses can be performed effectively. Therefore, eye related symptoms such as eye fatigue, eye dryness, eye pruritus, and eye pain can be reduced or relieved, and a cool fresh sensation in the eyes can be maintained for a long period of time.
- the water soluble polymer is added to moisten and lubricate the eyes, and also helps to keep the ingredients beneficial to the eyes in contact with the contact lens.
- the composition for contact lenses includes one or more vitamins (e.g., A, B and E)
- the vitamin(s) can be attached to the surface of the contact lens by interacting with the water soluble polymer.
- the water soluble polymer includes PEG 400 and MPC in a molar ratio of 1:20.
- the content of the water soluble polymer is in the range between 0.05% (w/v) and 5% (w/v).
- Comparative Examples 1-5 and Comparative Examples 1-2 are shown in Table 1. Each of the compositions obtained respectively in Comparative Examples 1-5 and Comparative Examples 1-2 was used in full contact with the contact lenses. The contact lenses were then put on the user's eyes, and a VAS (Visual analogue scale) method was used to evaluate the sensations of lubrication, comfort, coolness, and moisture in the eyes during the period of initial wear (time 1) and after wearing for 30 minutes (time 2) and 60 minutes (time 3). The evaluation results of for the Comparative Examples 1-5 and the Comparative Examples 1-2 are shown in Table 2. Scores for each of the items, as shown in Table 2, are average scores calculated from three users (i.e., six eyes).
- Table 1 unit g Examples Comparative ex 1 2 3 4 5 1 2 water 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 sodium chloride 10-20 10-20 10-20 10-20 10-20 10-20 boric acid 8-16 8-16 8-16 8-16 8-16 8-16 sodium tetraborate 0.5-4.5 0.5-4.5 0.5-4.5 0.5-4.5 0.5-4.5 0.5-4.5 TWEEN 80TM 0.01-5 0.01-5 - 0.01-5 0.01-5 - - PVP 0.01-5 0.01-5 0.01-5 0 0.01-5 - - GEROPONTM SBFA-30 0 0.01-5 0.01-5 0 0.01-5 - - polyoxyethylene hardened castor oil - - - 0.01-2.5 0.01-2.5 - - Hyaluronic acid (HA) 0-50 0-50 0-50 0-50 0-50 - 0-50 PEG400 0-50 0-50 0-50 0-50 0-50 - 0-50 MPC 0-50 0-50 0-50 0-50 0-50
- composition for contact lenses in which the algefacient and the surfactant are cooperatively used and the surfactant is sodium lauroyl lactylate. Accordingly, the expression of the algefacient can be performed effectively, so that the discomfort and foreign matter sensation in the eyes of contact lens wearers can be reduced or relieved, and long-lasting cool and moist sensations can be provided to the eyes.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Eyeglasses (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW106111144A TWI607768B (zh) | 2017-03-31 | 2017-03-31 | 隱形眼鏡用組成物及隱形眼鏡的保養方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3382002A1 EP3382002A1 (en) | 2018-10-03 |
EP3382002B1 true EP3382002B1 (en) | 2021-08-04 |
Family
ID=60021863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17190771.0A Active EP3382002B1 (en) | 2017-03-31 | 2017-09-13 | Composition for contact lens |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3382002B1 (ja) |
JP (1) | JP6652530B2 (ja) |
TW (1) | TWI607768B (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI798452B (zh) * | 2019-06-17 | 2023-04-11 | 晶碩光學股份有限公司 | 隱形眼鏡產品 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3070395A (en) * | 1994-07-22 | 1996-02-22 | Alcon Laboratories, Inc. | Use of low molecular weight amino acids in ophthalmic compositions |
US5494937A (en) * | 1994-07-22 | 1996-02-27 | Alcon Laboratories, Inc. | Saline solution for treating contact lenses |
US6228323B1 (en) * | 1996-12-13 | 2001-05-08 | Alcon Laboratories, Inc. | Multi-purpose compositions containing an alkyl-trypsin and methods of use in contact lens cleaning and disinfecting |
JP5437350B2 (ja) * | 2000-12-28 | 2014-03-12 | ロート製薬株式会社 | 眼科用組成物 |
JP4135905B2 (ja) * | 2003-03-17 | 2008-08-20 | ロート製薬株式会社 | 清涼化剤を含有するコンタクトレンズ用点眼剤 |
JP2012072183A (ja) * | 2004-06-08 | 2012-04-12 | Rohto Pharmaceutical Co Ltd | 眼科用清涼組成物 |
JP2007297559A (ja) * | 2006-05-02 | 2007-11-15 | Rohto Pharmaceut Co Ltd | アミノ酸修飾−(γ−ポリグルタミン酸)またはその塩、およびこれらの用途 |
US20080095754A1 (en) * | 2006-10-18 | 2008-04-24 | Burke Susan E | Ophthalmic compositions comprising diglycine |
JP5401113B2 (ja) * | 2008-02-07 | 2014-01-29 | ロート製薬株式会社 | メントール類を含有する亜塩素酸類化合物含有水性組成物 |
JP4457237B1 (ja) * | 2009-07-30 | 2010-04-28 | 株式会社シード | コンタクトレンズ用溶液 |
WO2011040572A1 (ja) * | 2009-09-30 | 2011-04-07 | ロート製薬株式会社 | 眼科組成物 |
TWI480039B (zh) * | 2011-03-10 | 2015-04-11 | Pegavision Corp | 一種用於隱形眼鏡之液態組成物 |
NZ700848A (en) * | 2012-06-14 | 2016-08-26 | Novartis Ag | Azetidinium-containing copolymers and uses thereof |
JP6654340B2 (ja) * | 2013-04-12 | 2020-02-26 | ロート製薬株式会社 | コンタクトレンズ用組成物およびそれを用いたコンタクトレンズパッケージ |
KR101490344B1 (ko) * | 2013-07-05 | 2015-02-11 | 마준오 | 냉감코팅층이 구비된 콘텍트렌즈 |
US20170056335A1 (en) * | 2014-04-09 | 2017-03-02 | Rhoto Pharmaceutical Co., Ltd. | Ophthalmic Composition |
JP6616137B2 (ja) * | 2015-09-15 | 2019-12-04 | 株式会社メニコン | コンタクトレンズ用組成物 |
US20170087199A1 (en) * | 2016-02-10 | 2017-03-30 | Senomyx, Inc. | Compositions for delivering a cooling sensation |
-
2017
- 2017-03-31 TW TW106111144A patent/TWI607768B/zh active
- 2017-08-29 JP JP2017164517A patent/JP6652530B2/ja active Active
- 2017-09-13 EP EP17190771.0A patent/EP3382002B1/en active Active
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Publication number | Publication date |
---|---|
EP3382002A1 (en) | 2018-10-03 |
JP2018173618A (ja) | 2018-11-08 |
JP6652530B2 (ja) | 2020-02-26 |
TW201836650A (zh) | 2018-10-16 |
TWI607768B (zh) | 2017-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wolffsohn et al. | Crossover evaluation of silicone hydrogel daily disposable contact lenses | |
Stern et al. | Comparison of the performance of 6-or 30-night extended wear schedules with silicone hydrogel lenses over 3 years | |
JP6871334B2 (ja) | コンタクトレンズ用組成物およびそれを用いたコンタクトレンズパッケージ | |
Campbell et al. | Clinical benefits of a new multipurpose disinfecting solution in silicone hydrogel and soft contact lens users | |
JP5568174B1 (ja) | コンタクトレンズパッケージ、およびコンタクトレンズ用パッケージング液 | |
Sankaridurg et al. | The future of silicone hydrogels | |
CN112094582A (zh) | 能增加湿润感的隐形眼镜溶液及包含其的隐形眼镜产品 | |
González-Méijome et al. | Clinical performance and “ex vivo” dehydration of silicone hydrogel contact lenses with two new multipurpose solutions | |
EP3382002B1 (en) | Composition for contact lens | |
Malet | An acute clinical comparison of corneal staining and comfort associated with contact lens care solutions | |
JP2019073494A (ja) | 抗アレルギー効果を有する液体組成物及び眼用製品 | |
JP6766121B2 (ja) | 眼科製品及びその眼科組成物 | |
CN109718376B (zh) | 具有抗敏舒缓效果的眼用产品 | |
Guthrie et al. | Exploring the factors which impact overall satisfaction with single vision contact lenses | |
CN108690740A (zh) | 隐形眼镜用组合物及隐形眼镜的保养方法 | |
TWI848653B (zh) | 隱形眼鏡 | |
Luensmann et al. | The impact of cosmetics on the physical dimension and optical performance of contemporary silicone hydrogel contact lenses | |
IE58311B1 (en) | Ophthalmic solutions and methods for improving the comfort and safety of contact lenses | |
CN110564519A (zh) | 眼科产品及其眼科组合物 | |
Lakkis et al. | Clinical investigation of asmofilcon a silicone hydrogel lenses | |
WO2019232717A1 (zh) | 眼科产品及其眼科组合物 | |
Wong et al. | In Vivo Wettability of HydraGlyde® Silicone Hydrogel Lens With and Without HydraGlyde® Containing Lens Care Solution | |
TW201517938A (zh) | 隱形眼鏡用組成物及使用有該隱形眼鏡用組成物的隱形眼鏡盒 | |
EP2642333B1 (en) | Soft contact lens application method | |
Iyamu et al. | Effect of soft contact lens materials on tear film stability and central corneal radius of curvature: A comparative study of Polymacon and Lotrafilcon B |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190328 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20190611 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20210217 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
INTC | Intention to grant announced (deleted) | ||
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1417015 Country of ref document: AT Kind code of ref document: T Effective date: 20210815 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602017043248 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20210804 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1417015 Country of ref document: AT Kind code of ref document: T Effective date: 20210804 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211104 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211206 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211104 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211105 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602017043248 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20210930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20220506 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210913 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210913 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210930 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210930 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230524 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20170913 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240919 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240917 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240919 Year of fee payment: 8 |